Abstract
A Phase II Study of Once Weekly Carfilzomib, Lenalidomide, Dexamethasone, and Isatuximab in Newly Diagnosed, Transplant-Eligible Multiple Myeloma
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have